Press

First Patient Implanted with VisiPlate® Glaucoma Treatment Device in the SAPPHIRE Trial

The first VisiPlate surgery in the US for the SAPPHIRE Trial was performed by Dr. Snyder of Sacramento Eye Consultants, in Sacramento, California. SAPPHIRE Trial is a prospective, multicenter, open-label clinical trial with 1-year follow up, evaluating safety and effectiveness of VisiPlate® aqueous shunt in glaucoma patients. VisiPlate® shunt is uniquely designed: novel metamaterial, thinner […]

Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate® Aqueous Shunt at AAO 2025

Almost half of patients medication free at 12 months. Vast majority of patients achieved significant IOP reduction on the same or fewer medications. Strong 12-month safety and efficacy results: no serious adverse events. Redwood City, CA – November 3, 2025 – /eyewire/ Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, presented […]

Ophthalmology Times Cutting-Edge Advancements Avisi Technologies FDA, IDE

Avisi Technologies’ investigational device exemption for VisiPlate approved by FDA

Key Takeaways VisiPlate’s IDE approval allows clinical studies in the US, focusing on safety and effectiveness data collection for the novel glaucoma treatment device. The device’s unique metamaterial and multichannel design aim to reduce IOP and minimize blockage risks, offering potential advantages over current surgical treatments. VITA trial results demonstrated a 40.4% mean IOP reduction […]

Avisi Technologies Receives FDA Approval to Study Novel Approach to Glaucoma Treatment

Avisi Receives FDA Approval to Study Novel Approach to Glaucoma Treatment

• Approved SAPPHIRE trial is a prospective, multicenter, open-label clinical trial with 1-year follow up, evaluating safety and effectiveness of VisiPlate® aqueous shunt in glaucoma patients. • VisiPlate® shunt is uniquely designed: novel metamaterial, thinner than a human hair, aiming for longevity, comfort, and aesthetics. • The multiple, redundant microchannels provide sustained aqueous flow while […]

Avisi Technologies Presents Positive Six-Month Clinical Data for VisiPlate® Aqueous Shunt at the American Glaucoma Society

REDWOOD CITY, Calif., April 2, 2025 /PRNewswire/ — Avisi Technologies, a clinical-stage ophthalmic device company, today announced encouraging six‐month interim results from the VITA trial evaluating its VisiPlate® device, an ultrathin, multichannel aqueous shunt in study subjects diagnosed with open-angle glaucoma. Data were presented by Eydie Miller-Ellis, MD, as a Top Paper at the American […]

Avisi Technologies Thought Leadership Impact at LSI US ’25

Recap of Avisi CEO’s Participation in Two Impactful Panels at LSI Emerging Medtech Summit Avisi Technologies returns to the Life Science Intelligence (LSI) stage with CEO Rui Jing Jiang participating in several panel discussions at the 2025 MedTech Summit. The panel discussions involved leadership and design strategies for achieving success within the MedTech industry. Life […]